Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announces that its New Drug Application for surufatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors has been accepted for review by the China National Medical Products Administration.